Citations

Clear

7546 citation(s) found for "Ku, Matthew".

Adiposity distribution and risks of 12 obesity-related cancers: a Mendelian randomization analysis
Hazelwood, Emma , Goudswaard, Lucy J. , Lee, Matthew A. , Vabistsevits, Marina , Pournaras, Dimitri J. , Buchanan, Daniel D. , Gruber, Stephen B. , Gsur, Andrea , Li, Li , Vodičková, Ľudmila , Grant, Robert C. , Samadder, N. Jewel , Timpson, Nicholas J. , Vincent, Emma E. , Brenner, Hermann , Buchanan, Daniel D , Gruber, Stephen B , Gsur, Andrea , Li, Li , Vodickova, Ludmila , Samadder, N Jewel , Gunter, Marc J , Yarmolinsky, James , Richardson, Tom G , Freisling, Heinz , Vincent, Emma E , Hazelwood, Emma , Brenner, Hermann , Gunter, Marc J. , Schuster‐Böckler, Benjamin , Murphy, Neil

Mayo Clinic

JNCI: Journal of the National Cancer Institute | September 12, 2025 | Volume: 117 | Issue: 12 | Pages: 2621-2642

10.1093/jnci/djaf201 | PMID 40987470 Get It

Abstract Introduction There is convincing evidence that overall adiposity increases the risks of several cancers. Whether the distribution of adiposity plays a similar role is unclear. Methods We used 2-sample Mendelian randomization (MR) to examine causal relationships of 5 adiposity distribution traits (abdominal subcutaneous adipose tissue (ASAT); visceral adipose tissue (VAT); gluteofemoral adipose tissue (GFAT); liver fat; and pancreas fat) with the risks of 12 obesity-related cancers (endometrial, ovarian, breast, colorectal, pancreas, multiple myeloma, liver, kidney (renal cell), thyroid, gallbladder, esophageal adenocarcinoma, and meningioma). Results Sample size across all genome-wide association studies (GWAS) ranged from 8407 to 728 896 (median: 57 249). We found evidence that higher genetically predicted ASAT increased the risks of endometrial cancer, liver cancer, and esophageal adenocarcinoma (odds ratios (OR) and 95% confidence intervals (CI) per standard deviation (SD) higher ASAT = 1.79 (1.18 to 2.71), 3.83 (1.39 to 10.53), and 2.34 (1.15 to 4.78), respectively). Conversely, we found evidence that higher genetically predicted GFAT decreased the risks of breast cancer and meningioma (ORs and 95% CIs per SD higher genetically predicted GFAT = 0.77 (0.62 to 0.97) and 0.53 (0.32 to 0.90), respectively). We also found evidence for an effect of higher genetically predicted VAT and liver fat on increased liver cancer risk (ORs and 95% CIs per SD higher genetically predicted adiposity trait = 4.29 (1.41 to 13.07) and 4.09 (2.29 to 7.28), respectively). Discussion Our analyses provide novel insights into the relationship between adiposity distribution and cancer risk. These insights highlight the potential importance of adipose tissue distribution alongside maintaining a healthy weight for cancer prevention.
Medical guidelines for fibrodysplasia ossificans progressiva
Kaplan, Frederick S. , Mukaddam, Mona Al , Hidalgo‐Bravo, Alberto , Brown, Matthew A. , Cali, Amanda, Crowe, C. R., Cunto, Carmen L. De, Delai, Patricia , Diecidue, Robert J. , Friedman, Clive, Grunwald, Zvi, Haga, Nobuhiko , Kitterman, Joseph A., Levy, Charles E. , Morhart, Rolf, Netelenbos, J.C., Shore, Eileen M. , Zasloff, Michael , Pignolo, Robert J. , Al Mukaddam, Mona , Hidalgo Bravo, Alberto , Brown, Matthew , Friedlander, Lisa , Hsiao, Edward C , Shore, Eileen M , Pignolo, Robert J , Kaplan, Frederick S , Baujat, Geneviève , Cho, Tae‐Joon , Crowe, Corrie, Cunto, Carmen De , Eekhoff, Elisabeth M. W. , Hsiao, Edward C. , Keen, Richard , Madhuri, Vrisha , Scott, Christiaan , Zhang, Ke‐Qin

Mayo Clinic

JBMR Plus | September 11, 2025 | Volume: 9 | Issue: 11 | Pages: No page available

10.1093/jbmrpl/ziaf150 | PMID 41143155 Get It

Abstract Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic condition characterized by congenital malformations of the great toes and progressive heterotopic ossification (HO) in specific anatomic patterns. Present management summarized here is focused on early diagnosis, assiduous avoidance of injury and iatrogenic harm, symptomatic amelioration of painful flare-ups, and optimization of residual function. Twenty-one members of the International Clinical Council on FOP (ICC) and seven consultants from 15 countries, chosen for their clinical expertise in FOP, developed this summary statement. Further advances in therapeutics will be based on rigorous clinical trials to assess novel and emerging treatment and prevention strategies. A detailed and updated exploration of the topics outlined in this brief perspective can be found in “The Medical Management of Fibrodysplasia Ossificans Progressiva: Current Treatment Considerations” which can be found on the International Clinical Council on FOP (ICC) website (www.iccfop.org).
Eliminating Disparities in Otolaryngology Resident Application Selection
Bukowski, Emily E. K. , Bisco, Susan E. , Carducci, Valentina , Stokken, Janalee K. , Yin, Linda X , Bayan, Semirra L. , Carlson, Matthew L , Yin, Linda X. , Romero‐Brufau, Santiago

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | September 11, 2025 | Volume: 135 | Issue: 2 | Pages: 101-107

10.1177/00034894251363745 | PMID 40931850 Get It

Objective: To develop, implement, and evaluate a novel process used for residency application review that deemphasizes metrics known to create bias with the goal of interviewing and matching a more diverse resident cohort. Methods: Between 2020 and 2023, a novel standardized rubric and application review process were developed and implemented at the authors’ academic training program. The rubric deemphasized USMLE scores, honor society membership, and number of publications while utilizing an AI-driven pre-sort of applications, facilitating holistic review. This weighted applicant attributes identified in personal statements, life experiences, achievements in community, leadership roles, otolaryngology-specific impressions highlighted in letters of recommendation, and otolaryngology-specific research and publications similarly to academic metrics (clerkship grades and standardized test scores). Demographics of applicants interviewed and matched into our program were compared pre- and post-implementation using descriptive statistics. Results: Using a standardized rubric to review residency applications that deemphasizes traditional metrics, the authors’ otolaryngology residency program has interviewed, ranked, and matched more diverse candidates. As a result, from 2019 to 2022, the overall resident cohort has diversified from 4% historically marginalized residents to 24%, from 28% female residents to 44%, and from 33% of residents outside our geographic region to 66%. Conclusion: There is significant underrepresentation among otolaryngology residents. Selection based upon USMLE Step 1 scores, honor society membership, and number of publications have been shown to restrict diversity. Purposeful holistic review increases diversity in interviewed and matched resident cohort.
Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Benson, Al B. , D’Angelica, Michael I. , Ahmed, Aijaz, Akce, Mehmet , Anaya, Daniel A. , Are, Chandrakanth , Aye, Lydia, Baker, Marshall S., Binder, David C. , Burgoyne, Adam M. , Castellanos, Jason , Cloyd, Jordan M. , Franses, Joseph W. , Harris, William P., Iyer, Renuka , Jennings, Lawrence J. , Kelley, Robin Kate , Khan, Sajid , Palta, Manisha , Sahai, Vaibhav , Stein, Stacey , Stephans, Kevin L. , Thanikachalam, Kannan , Yano, Motoyo , Yopp, Adam C. , Zhao, Ken, Schonfeld, Ryan, Hochstetler, Cindy, Sahai, Vaibhav , Abrams, Thomas A. , Anders, Robert A. , Bachini, Melinda , Brown, Daniel B. , Cullinan, Darren R. , Glazer, Evan S. , Levine, Matthew H , Melstrom, Laleh , Raman, Steven S. , Ronnekleiv-Kelly, Sean M , Turk, Anita , Vauthey, Jean‐Nicolas , Venook, Alan P. , Zhao, Ken

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 10, 2025 | Volume: 23 | Issue: 9 | Pages: 403-418

10.6004/jnccn.2025.0042 | PMID 40930144 Get It

The NCCN Guidelines for Biliary Tract Cancers (BTCs) provide recommendations for the evaluation and comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. The multidisciplinary panel of experts is convened at least once annually to review requests from internal and external entities as well as to evaluate new data on current and emerging therapies. This manuscript focuses on the adjuvant chemotherapy and chemoradiation treatment options for BTCs as well as the systemic treatment recommendations for patients with advanced BTCs.
NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 7.2025
Riely, Gregory J. , Wood, Douglas E. , Aisner, Dara L. , Bauman, Jessica R. , Desai, Aakash , Dilling, Thomas J. , Durm, Gregory A. , Gettinger, Scott , Gubens, Matthew A. , Lackner, Rudy P., Levy, Benjamin, Maldonado, Fabien , Morgensztern, Daniel , Mullikin, Trey C. , Ng, Thomas, Owen, Dawn , Patel, Sandip Pravin , Riess, Jonathan W. , Mendez, Ana Lucia Ruano, Shapiro, Theresa A. , Singh, Aditi P. , Stevenson, James, Tam, Alda L. , Yau, Edwin , Gregory, Kristina M., Hang, Lisa, Desai, Aakash P , Loo, Billy W. , Axtell, Andrea L. , Bharat, Ankit , Chang, Joe Y. , Dowell, Jonathan E. , Grotz, Travis E. , Juloori, Aditya , Lanuti, Michael D. , Lin, Jules , Lovly, Christine Marie , Owen, Dwight H , Patil, Tejas , Polanco, Patricio Marcelo , Tanvetyanon, Tawee , Yanagawa, Jane

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 10, 2025 | Volume: 23 | Issue: 9 | Pages: 354-362

10.6004/jnccn.2025.0043 | PMID 40930154 Get It

The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of NSCLC. These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines, with a focus on systemic therapy options for the treatment of patients with nonmetastatic NSCLC and the corresponding molecular testing considerations.
Symptoms of Allodynia and Pain Thresholds Amongst Those with Acute Post-Traumatic Headache Attributed to Mild Traumatic Brain Injury: A Prospective, Longitudinal Study
Ziff, Noah, Garza, Santiago, Starling, Amaal J. , Esterov, Dmitry , Barrett, Kevin M. , Ross, Katherine , Anderson, Trent , Nikolova, Simona , Li, Jing, Huentelman, Matthew J. , Starling, Amaal, Dumkrieger, Gina , Garza, Santiago, Porreca, Frank , Navratilova, Edita , Wu, Teresa , Chong, Catherine D. , Schwedt, Todd J.

Mayo Clinic

No container title available | September 9, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7511029/v1 | PMID 40964034 Get It

Abstract Background Post-traumatic headache (PTH) is a common acute and persistent symptom following mild traumatic brain injury (mTBI). Symptoms of cutaneous allodynia and presence of nociceptive sensitization might be associated with acute PTH and its persistence. The objectives of this study were to compare allodynia symptoms and cutaneous heat pain thresholds amongst males and females with acute PTH to healthy controls (HC) and determine if pain thresholds and allodynia symptoms are associated with PTH outcomes. Methods This prospective longitudinal study enrolled 139 adults with acute PTH attributed to mTBI as defined by the International Classification of Headache Disorders and 95 HC. All PTH participants completed a baseline research visit near PTH onset and a follow-up visit three to four months later. All PTH participants and a subset of HC completed the Allodynia Symptom Checklist (ASC-12) at each research visit. A different subset of the participants underwent quantitative sensory testing (QST) during baseline, 4-week, and 16-week research visits to quantify cutaneous heat pain thresholds at the forehead and forearms. Data from daily headache diaries were used to determine longitudinal PTH improvement versus non-improvement at three months. ASC-12 score and pain threshold comparisons were made between PTH and HC groups, PTH improved versus non-improved cohorts, and between PTH males and females. Results Participants with PTH had an average age of 42.6 years and 64.0% were female. HC had an average age of 40.0 years and 65.3% were female. At the first visit, PTH participant ASC-12 scores averaged 3.6 versus 0.1 amongst HC, p < 0.001. 44.8% of PTH participants had headache improvement at 3 months. ASC-12 scores were higher in the PTH non-improved versus improved group at baseline (4.0 versus 2.4, p = 0.038) and 3-month follow-up (3.4 versus 1.9, p = 0.012). ASC-12 scores were higher in females than males at baseline (4.7 versus 1.6, p < 0.001) and 3-months (3.9 versus 1.2, p < 0.001). Cutaneous heat pain thresholds at the forehead and forearm did not differ between any group. Conclusions PTH attributed to mTBI is associated with symptoms of cutaneous allodynia. Greater allodynia symptoms are present in females with PTH compared to males and may be associated with PTH non-improvement.
Genomewide association study of a homogeneous multiple sclerosis cohort: Tumefactive demyelination
Zhao-Fleming, Hannah , Decker, Paul A. , Kosel, Matthew , Kollmeyer, Thomas , Clarkson, Benjamin D. , Jenkins, Robert B. , Tobin, W. Oliver , Eckel‐Passow, Jeanette E. , Kollmeyer, Thomas M. , Zhao-Fleming, Hannah H, Jenkins, Robert, Tobin, W Oliver , Eckel-Passow, Jeanette E , Decker, Paul A. , Drucker, Kristen , Lachance, Daniel Honore , Howe, Charles L.

Mayo Clinic

Multiple Sclerosis Journal | September 8, 2025 | Volume: 31 | Issue: 10 | Pages: 1167-1174

10.1177/13524585251371984 | PMID 40916898 Get It

Background: Tumefactive demyelination (TD) is a rare variant of multiple sclerosis (MS) characterized by tumor-like lesions that often require aggressive management. Genome-wide association studies (GWAS) identified variants associated with MS; similar analyses in TD are lacking. Objective: A GWAS was performed to identify variants associated with TD. Methods: The case–control study included 142 TD cases and 293 controls. TD patients were required to have a demyelinating event and magnetic resonance imaging (MRI) showing one or more lesions. Controls were patients without a neurologic or systemic inflammatory disease or cancer. Logistic regression was used to compare cases versus controls for each variant; age, sex, and principal components were included as covariates. A p -value threshold of 5 × 10 −8 was GWAS significant and 5 × 10 −6 nominally significant. A polygenic risk score (PRS) was compared across TD and controls. Results: Variants on chromosome 14 (rs117797734, p = 2.06 × 10 −11 , odds ratio (OR) = 13.14) and chromosome 6 (most significant rs6936540, p = 5.5 × 10 −7 , OR = 2.61) near DCBLD1 were significant. Seven non-MHC and two MHC variants associated with MS were associated with TD. The PRS was significantly higher in TD versus controls. Conclusion: We identified novel regions associated with TD, demonstrating the importance of performing GWAS in homogeneous subtypes of MS. Further validation and functional experiments are necessary.